Screener
Monopar Therapeutics MNPR Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other comprehensive income (loss): | ||
| Foreign currency translation gain (loss), net | (190) | 1,239 |
| Unrealized gain (loss) on investments, net | (32,678) | 346 |
| Comprehensive income (loss) | $(3,925,918) | $(2,623,387) |
| Net income (loss) per share: | ||
| Basic and diluted | $(0.46) | $(0.38) |
| Weighted average shares outstanding: | ||
| Basic and diluted | 8,535,443 | 6,987,381 |
Document
FAQ
- What is Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Monopar Therapeutics (MNPR) reported comprehensive income (loss), net of tax, attributable to parent of -$3.93M in Q1 2026.
- How has Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 49.7% year-over-year, from -$2.62M to -$3.93M.
- What is the long-term trend for Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 17.9% compound annual growth rate (CAGR), from -$7.02M to -$13.56M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as foreign currency adjustments and unrealized gains on securities. It provides a comprehensive view of the company's total financial performance and changes in net worth over a specific period. Investors use this to assess the broader impact of market and economic factors on the company's overall financial health.
Ask your AI about Monopar Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude